Please assess the completion status of the following clinical trial:

Trial Title: Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male 18-50 yrs old~* In good general health based on normal screening evaluation (consisting of medical history, physical exam, normal serum chemistry, hematology, and baseline hormone levels)~Exclusion Criteria:~* Poor general health, with abnormal blood results at screening~* A known history of alcohol or drug abuse~* Participation in a long-term male contraceptive study within three months of screening

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Lupron injection at Day -14 with load of dutasteride (24.5 mg) followed by 13 days of Dutasteride. On day 0, 11, 0.5 mg Dutasteride taken daily for next 11 days. Day 1 Oral Testosterone (T) 200mg without food, Day 2 Oral T 400 mg without food, Day 3 Oral T 400 mg with food. During the 2nd week of the study, we will repeat the testosterone doses, with a 2nd formulation of testosterone (Day8, 9, \& 10.

Based on this trial design, predict the completion outcome and termination type (if applicable).